Diagnostics Could be Value Driver for Ampio Pharma (AMPE) in FY14; Aegis Boosts PT

January 6, 2014 2:19 PM EST Send to a Friend
Get Alerts AMPE Hot Sheet
Price: $3.68 +7.92%

Rating Summary:
    2 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AMPE Now!
Join SI Premium – FREE
Aegis Capital maintains its Buy rating on Ampio Pharmaceuticals (AMEX: AMPE), but boosts its price target from $14 to $15.

Analyst Ram Selvaraju said that Ampio was now an important member of the diagnostic sector following news today that the company's Luoxis unit entered agreements with two universities for its ORP diagnostic system. For more color, click here. The analyst thinks diagnostics will be a key value driver in 2014.

Selvaraju also said, Ampio has also disclosed highly favorable efficacy and safety data with its lead drug candidate, Ampion™, in patients with knee osteoarthritis. The drug may have best-in-class efficacy in this indication. We believe that the company should be able to file for approval with positive data from a single Phase 3 confirmatory trial. In addition, an interim analysis of Ampio's 450-patient dose-finding 505(b)(2) trial of its diabetic macular edema (DME) drug candidate Optina found indications of a beneficial effect.

For an analyst ratings summary and ratings history on Ampio Pharmaceuticals click here. For more ratings news on Ampio Pharmaceuticals click here.

Shares of Ampio Pharmaceuticals closed at $6.22 last Friday, with a 52 week range of $3.54 - $10.86.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment